ABSTRACT A NAD(P)-linked 3a-hydroxysteroid dehydrogenase [3a-hydroxysteroid: NAD(P) oxidoreductase, EC 1.1.1.50], purified to homogeneity from male rat liver cytosol, accounts for most of the oxidative activity for 3a-hydroxysteroids and for benzenedihydrodiol (trans-1,2-dihydroxy-3,5-cyclohexadiene) of this tissue. This enzyme, which also promotes the reduction of quinones and certain aromatic aldehydes and ketones, is powerfully inhibited by the major types of nonsteroidal and steroidal anti-inflammatory drugs. The IC5o values for indomethacin and for betamethasone are in the low micromolar range. The rank order of the inhibitory potencies of a series of these agents paralleled closely that reported for the inhibition of cyclooxygenase by nonsteroidal anti-inflammatory agents or the indirect inhibition of phospholipase A2 by anti-inflammatory steroids. A good correlation is found also between the logarithm of the concentrations of these drugs required to inhibit 3ci-hydroxysteroid dehydrogenase and the human anti-inflammatory dose. The suggestion that this enzyme may play a role in mediating inflammation is further strengthened by the observation that the dehydrogenase binds arachidonic acid and is also potently inhibited by certain prostaglandins. This enzyme may be of use in the evaluation of anti-inflammatory activity.
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A dual nicotinamide nucleotide-dependent 3a-hydroxysteroid dehydrogenase [3a-hydroxysteroid: NAD(P) oxidoreductase, EC 1.1.1.50] was first described in rat liver cytosol by Tomkins (ref. 1; reviewed in ref. 2) . This enzyme has attracted attention because it catalyzes an early step in the metabolism of steroid hormones, and because its activity is androgen-dependent in some tissues (3, 4) . Recently, Vogel et aL (5) reported that dihydrodiol dehydrogenase of rat liver copurifies with 3a-hydroxysteroid dehydrogenase. Attention has been directed to the participation of this enzyme in the detoxification of metabolites of polycyclic aromatics. Thus, by oxidizing trans-dihydrodiols to catechols, this enzyme may suppress conversion of such diols to diol epoxides which are potent ultimate carcinogens (6) .
This paper demonstrates that the purified 3a-hydroxysteroid dehydrogenase is potently inhibited by many nonsteroidal and steroidal anti-inflammatory drugs at concentrations comparable to those inhibiting their commonly considered target enzymes-i.e., cyclooxygenase and phospholipase A2, respectively. Furthermore, the order of potency of inhibition of the dehydrogenase by these drugs parallels that observed for their presumed target enzymes.
MATERIALS AND METHODS
Anti-inflammatory compounds were donated by the manufacturers. Steroids were obtained from Steraloids (Wilton, NH).
1-Acenaphthenol, 1,4-benzoquinone, and 1,2-naphthoquinone (Aldrich) were recrystallized before use. 9,10-Phenanthrenequinone, 4-nitroacetophenone, and 4-carboxybenzaldehyde were products of Fluka-Tridom (Hauppauge, NY). Benzenedihydrodiol was synthesized (7) .
Preparation of 3a-Hydroxysteroid Dehydrogenase. This enzyme was purified to homogeneity from the 40-75% ammonium sulfate fraction of liver cytosol of male Sprague-Dawley rats. The ammonium sulfate fraction was subjected to successive chromatography on DEAE-cellulose and hydroxylapatite followed by Chromatofocusing and gel filtration on Sephadex G-100. The homogeneous enzyme had the following specific activities: 3. Comparison of the inhibition of dehydrogenase with that of cyclooxygenase is complicated by the wide range of sensitivity of cyclooxygenase preparations to inhibition by indomethacin. The cyclooxygenase from human synovium is potently inhibited by indomethacin (IC50 = 3 nM) whereas the enzymes from rabbit brain or kidney or goat seminal vesicle require micromolar concentrations for inhibition (18) . Even for cyclooxygenase preparations from a single source (e. g., bovine seminal vesicle), the IC50 values reported by several laboratories differ greatly, from a low of 0.07 ,M to a high of 20 ,uM (18 Our findings suggest that the 3a-hydroxysteroid dehvdrogenase might be a useful screen for anti-inflammatorv activity. We have found that, for a series of indomethacin analogues, the IC50 values for the inhibition of androsterone oxidation were 0.9, 10.0, and 7.0 tLM for Z-sulindac sulfide, E-sulindac sulfide, and sulindac, respectively. This is in agreement with the enhancement of the activity of sulindac upon reduction of the sulfone to the sulfide and with the finding that the Z isomer is a much more potent inhibitor of inflammation than the E isomer (18) . However, for at least one pair of enantiomers, (+)-and (-)-naproxen, both isomers were equipotent inhibitors of the dehydrogenase, whereas the S (+) enantiomer is more active both as a cyclooxygenase inhibitor and as an anti-inflammatory agent (19 sone of the reduction of 9, 10-phenanthrenequinone and oxidation of androsterone were 1.20 and 3.97 aM, respectively. The order of potency for the inhibition of these reactions by anti-inflammatory steroids also correlated well with their pharmacological effects in the granuloma and glycogen deposition assays (Table 2) (22) . Thus, betamethasone and dexamethasone were the most potent inhibitors of the dehydrogenase; cortisol and cortisone were no more than 1% as effective. 6a-Methylprednisolone, prednisolone, and prednisone were equipotent and were approximately 20-30 times more potent than cortisone. The inhibitory potency of steroidal anti-inflammatory drugs for 3a-hydroxysteroid dehydrogenase agreed well with that observed for their indirect inhibition of phospholipase A2. Measurement of phospholipase A2 inhibition after the exposure of guinea pig lung to rabbit aorta contracting substance releasing factor gave the following IC50 values for the inhibition of the release of prostaglandin H2 (PGH2): 3.5 ,uM for dexamethasone and betamethasone and 120 ,uM for cortisone (23) . Furthermore, there is a close correlation between the logarithm of IC50 values of these drugs for their inhibition of 3a-hydroxysteroid dehydrogenase (9, 10-phenanthrenequinone reduction) and the recommended daily dose to produce an anti-inflammatory effect (r = 0.882; n = 7).
The inhibition of 3a-hydroxysteroid dehydrogenase by antiinflammatory steroids is competitive (Ki, 18 Although 3a-hydroxysteroid dehydrogenase binds certain PGs, it does not appear to possess 9-ketoreductase or 15-hydroxy-PG dehydrogenase activities. Large scale incubations of PGE1 in the presence of NADH or NADPH (for 9-ketoreductase activity) and of PGE2 with NAD or NADP (for 15-hydroxy-PG dehydrogenase activity) in the presence of the purified enzyme, followed by extraction at pH 4.0 and thin layer chromatography, led to the recovery of starting material only. Furthermore, none of the described PG dehydrogenases has dual nucleotide specificity (24) .
Molecular Modeling of Androsterone and Indomethacin. Gund and Shen (25) have pointed out analogies between a specific conformation of arachidonic acid and the crystal structure of indomethacin. Alternative models emphasize conformational similarities between nonsteroidal anti-inflammatory drugs and a postulated transition state of the cyclooxygenase reaction (26) .
The substrate and inhibitor specificities of the 3a-hydroxysteroid dehydrogenase may be rationalized by substantial conformational similarities between indomethacin and androsterone when the docked molecules are viewed either from the front face of the steroid or from the side (Fig. 4) . Two Finally, the presence on 3a-hydroxysteroid dehydrogenase of a common binding site for PGs and steroidal and nonsteroidal anti-inflammatory drugs suggests that these agents may regulate the capacity of the enzyme to metabolize steroids, including androgens (e.g., Sa-dihydrotestosterone) and to inactivate certain xenobiotics (e.g., trans-dihydrodiols).
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